Paper TrailKOREA
Why Korean and U.S. stocks moved, checked against filings
· Updated

Why Samchundang Pharm Fell 14.6% While KOSDAQ Rose 2%

Samchundang Pharm closed down 14.56% at 137,300 won on a day KOSDAQ gained 1.96%. Recent filings give no reason; only a press report of a U.S. approval setback.

Why Samchundang Pharm Fell 14.6% While KOSDAQ Rose 2%

Seoul — Samchundang Pharm closed down 14.56% at 137,300 won on Nov. 18, while KOSDAQ rose 1.96%. Did a filing confirm a company problem? Not yet. The recent DART filing list holds two exchange notices on stock-futures price limits and two Nov. 2 filings on a Japan contract. None explains the drop.

pharmaceutical laboratory

At a glance

Stock Why it fell Verdict Evidence What to check next
Samchundang Pharm An intraday report said U.S. approval of its Eylea biosimilar hit a snag. No company filing. Reason not confirmed Press report only Company statement or DART filing; investor flows

Samchundang Pharm, down 14.56% today, but no filing gives a reason

Samchundang Pharm recent price and volume

The market is not the explanation. KOSPI rose 1.99% and KOSDAQ 1.96% as sentiment recovered after Nvidia's earnings. Intraday coverage described Samchundang as the lone weak name despite KOSDAQ's gain.

On filings: the two Nov. 18 items are exchange notices that the stock-futures price-limit expansion thresholds were hit on the downside. They report the move; they do not explain it. On Nov. 2 the company filed both the signing and the termination of an exclusive Japan sales and supply contract for SCD411, an aflibercept biosimilar, at the same time. The titles alone do not show how the two relate, or whether either connects to today's drop.

There is one press report. Newdaily Economy wrote at 12:22 p.m. that U.S. approval of the Eylea biosimilar was held up and that the company would resubmit supplementary data. The company has not confirmed this in a filing. So the verdict is 'reason not confirmed', evidence 'press report only'. The other side of the ledger is also empty: no treasury-share disposal, equity offering or insider sale appears in the recent list. Investor-flow data was not available for this article, so we could not check who sold.

How far has it fallen? The five-day drop is 26.5%. The stock is 44.3% below its three-month closing high of 246,500 won on Oct. 6, and down 18.6% since Aug. 21. It jumped from the 170,000s to the 240,000s in three sessions in early October before giving it back. RSI(14) is 26.3, a short-term oversold zone. It sits at the bottom 1% of its 52-week range and 23.1% below its 20-day average. Volume is about 24 times normal. No earnings-strength data was available. These numbers describe the drop; they are not a buy signal.

Two things to check next. Does the company confirm or deny the U.S. approval report in a filing, and does the exchange ask for a disclosure? And do foreign and institutional flows, missing from this data, point one way over the coming days?

← Latest · Daily movers archive